Mutual, Hikma Settle Suit Over Unapproved Gout Drug

Law360, New York (October 20, 2010, 7:28 PM EDT) -- U.K.-based Hikma Pharmaceuticals PLC's U.S. unit has settled a lawsuit with Mutual Pharmaceutical Co. Inc. over the gout treatment Colcrys, agreeing to stop selling a competing version of the medication until it gets regulatory approval.

Judge Garrett E. Brown Jr. of the U.S. District Court for the District of New Jersey signed off on a stipulation of dismissal Wednesday between Hikma's West-Ward Pharmaceutical Corp. and Mutual, a subsidiary of URL Pharma Inc.

Hikma said it has stopped selling oral colchicine tablets until it receives approval for...
To view the full article, register now.